|Day's range||220.00 - 227.00|
|52-week range||174.00 - 255.00|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
The U.S. Food and Drug Administration approved Merrimack Pharmaceutical Inc's pancreatic cancer therapy Onivyde, but with a serious warning, marking the company's first ever drug to win regulatory clearance. The drug in combination with chemotherapy treatments 5-fluorouracil and leucovorin treats metastatic pancreatic cancer in patients, who have failed to respond to chemotherapy drug gemcitabine. Onivyde, however, carries a black box warning about severe risks of diarrhea and low white blood cell count, the agency said, adding that it was not approved for use as a single agent.
The U.S. Food and Drug Administration approved Merrimack Pharmaceutical Inc's pancreatic cancer therapy, Onivyde, making it the company's first approved drug. Onivyde, when used in combination with chemotherapy ...